Cyclo Reports Progress in NPC Drug

Some of the more exotic health-care stocks are making headlines these days, particularly, Gainesville, Florida-bassd Cyclo Therapeutics, Inc. (OTC:CTDH), which used to be known as CTD Holdings.

The biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced Tuesday that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C (NPC) patients.

Said CEO Scott Fine, "Today’s ‘Last-Patient-In’ announcement… completes another important step in our development and registration strategies for Trappsol® Cyclo to treat NPC, a disease which causes much suffering for the patients and their families. We are delighted to share this news with our many supporters and all of our stakeholders."

Niemann-Pick Disease Type C is a rare and fatal genetic disease affecting one in 100,000 live births globally. NPC affects every cell in the body due to a defect in the NPC protein which is responsible for cholesterol processing in the cell. NPC causes symptoms in the brain, liver, spleen, lung and other organs.

There are no approved drug therapies for NPC in the United States and only one approved therapy in Europe.

Shares in CTDH grabbed a penny, or 5.9%, to 18 cents, on 38,000 shares in Tuesday’s final hour of trade.